Analyst Consensus ?
ConsensusHold36 ratings
Bullish1541.7%
Neutral1644.4%
Bearish513.9%
FN2 Earnings Intelligence
CME Group Inc. analyst ratings
CME Group Inc. (CME) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$260Previous close
$151Low
$255.17Average
$330High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 23, 2026 |
| JP Morgan | Underweight | Underweight | Maintain | Jul 23, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 23, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 9, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 8, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 6, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Jul 2, 2026 |
| Keefe, Bruyette & Woods | Outperform | Market Perform | Upgrade | Jun 18, 2026 |
| Rothschild & Co | Buy | Neutral | Upgrade | Jun 11, 2026 |
| Erste Group | Hold | Buy | Downgrade | Jun 5, 2026 |
| Argus Research | Hold | Buy | Downgrade | Mar 4, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Feb 5, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Oct 23, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Sep 25, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 24, 2025 |
| Redburn Atlantic | Neutral | Buy | Downgrade | Oct 8, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Oct 3, 2024 |
| Rosenblatt | Sell | Sell | Maintain | Apr 25, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 9, 2023 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Jun 10, 2022 |
| Wells Fargo | Overweight | Equal Weight | Upgrade | Feb 25, 2021 |
| CFRA | Hold | Hold | Maintain | Apr 29, 2020 |
| Berenberg | Hold | Buy | Downgrade | Sep 19, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jan 11, 2019 |
| Jefferies | Buy | Buy | Maintain | Jul 17, 2017 |
| Keefe Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 29, 2016 |
| CLSA | Underperform | Underperform | Maintain | Jul 14, 2016 |
| Evercore ISI Group | Buy | Hold | Upgrade | May 8, 2015 |
| Compass Point | Neutral | Neutral | Maintain | Oct 21, 2013 |
| ISI Group | Buy | Neutral | Upgrade | Jun 14, 2013 |
| Macquarie | Neutral | Outperform | Downgrade | May 21, 2013 |
| Evercore Partners | Equal Weight | Overweight | Downgrade | Oct 26, 2012 |
| BGB Securities | Hold | Hold | Maintain | Oct 26, 2012 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Oct 8, 2012 |
| Stifel | Hold | Buy | Downgrade | Oct 8, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $260. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Michael Cyprys | $330 | $252.8 | +26.9% | Jul 23, 2026 |
| Piper Sandler | Analyst unavailable | $295 | $243.61 | +13.5% | Jul 15, 2026 |
| Morgan Stanley | Analyst unavailable | $324 | $237.46 | +24.6% | Jul 10, 2026 |
| UBS | Alex Kramm | $260 | $236.6 | +0.0% | Jul 6, 2026 |
| Piper Sandler | Patrick Moley | $320 | $248.12 | +23.1% | Jun 17, 2026 |
| Piper Sandler | Patrick Moley | $329 | $267.85 | +26.5% | Jun 15, 2026 |
| Redburn Partners | Analyst unavailable | $323 | $263.8 | +24.2% | Jun 11, 2026 |
| Morgan Stanley | Michael Cyprys | $353 | $282.44 | +35.8% | Apr 23, 2026 |
| Barclays | Analyst unavailable | $316 | $285.71 | +21.5% | Apr 23, 2026 |
| Morgan Stanley | Analyst unavailable | $362 | $294.82 | +39.2% | Apr 10, 2026 |
| UBS | Analyst unavailable | $310 | $297.38 | +19.2% | Feb 6, 2026 |
| RBC Capital | Ashish Sabadra | $302 | $300.42 | +16.2% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $340 | $294.62 | +30.8% | Feb 5, 2026 |
| Barclays | Benjamin Budish | $312 | $294.62 | +20.0% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $319 | $273.41 | +22.7% | Jan 15, 2026 |
| Morgan Stanley | Michael Cyprys | $320 | $269.09 | +23.1% | Dec 22, 2025 |
| Barclays | Analyst unavailable | $304 | $272.42 | +16.9% | Dec 12, 2025 |
| Morgan Stanley | Michael Cyprys | $314 | $269.5 | +20.8% | Oct 23, 2025 |
| UBS | Alex Kramm | $280 | $267.81 | +7.7% | Oct 23, 2025 |
| Deutsche Bank | Analyst unavailable | $300 | $269.59 | +15.4% | Oct 23, 2025 |
| Raymond James | Patrick O'Shaughnessy | $307 | $271.45 | +18.1% | Oct 13, 2025 |
| Barclays | Analyst unavailable | $280 | $263.6 | +7.7% | Oct 8, 2025 |
| Morgan Stanley | Analyst unavailable | $312 | $264.46 | +20.0% | Oct 1, 2025 |
| UBS | Alex Kramm | $285 | $261.78 | +9.6% | Sep 8, 2025 |
| Barclays | Benjamin Budish | $298 | $277.18 | +14.6% | Jul 24, 2025 |
| Raymond James | Patrick O'Shaughnessy | $287 | $254.57 | +10.4% | Mar 10, 2025 |
| Oppenheimer | Owen Lau | $258 | $227.43 | -0.8% | Oct 24, 2024 |
| Barclays | Benjamin Budish | $231 | $227.14 | -11.2% | Oct 24, 2024 |
| Citigroup | Christopher Allen | $250 | $223.57 | -3.8% | Oct 3, 2024 |
| RBC Capital | Ashish Sabadra | $235 | $218.47 | -9.6% | Sep 26, 2024 |
| Bank of America Securities | Craig Siegenthaler | $177 | $215.74 | -31.9% | Sep 3, 2024 |
| Deutsche Bank | Brian Bedell | $193 | $198.92 | -25.8% | Jul 25, 2024 |
| Piper Sandler | Patrick Moley | $225 | $199.38 | -13.5% | Jul 25, 2024 |
| Barclays | Benjamin Budish | $209 | $197.25 | -19.6% | Jul 25, 2024 |
| UBS | Alex Kromm | $250 | $203.78 | -3.8% | Jun 5, 2024 |
| Rosenblatt Securities | Andrew Bond | $187 | $212.59 | -28.1% | Apr 25, 2024 |
| Barclays | Benjamin Budish | $228 | $212.59 | -12.3% | Apr 25, 2024 |
| Deutsche Bank | Brian Bedell | $210 | $212.21 | -19.2% | Apr 5, 2024 |
| Credit Suisse | Analyst unavailable | $198 | $174.76 | -23.8% | Feb 7, 2023 |
| Morgan Stanley | Analyst unavailable | $196 | $176.93 | -24.6% | Jan 11, 2023 |
| Piper Sandler | Analyst unavailable | $250 | $171.12 | -3.8% | Dec 19, 2022 |
| Credit Suisse | Analyst unavailable | $210 | $194.69 | -19.2% | Sep 6, 2022 |
| Rosenblatt Securities | Analyst unavailable | $171 | $205.46 | -34.2% | Aug 17, 2022 |
| Deutsche Bank | Analyst unavailable | $212 | $202.14 | -18.5% | Aug 12, 2022 |
| Credit Suisse | Analyst unavailable | $216 | $198.24 | -16.9% | Aug 3, 2022 |
| UBS | Analyst unavailable | $240 | $195.34 | -7.7% | Aug 2, 2022 |
| Morgan Stanley | Analyst unavailable | $226 | $198.5 | -13.1% | Jul 28, 2022 |
| Credit Suisse | Analyst unavailable | $218 | $195.99 | -16.2% | Jul 28, 2022 |
| Morgan Stanley | Analyst unavailable | $242 | $201.51 | -6.9% | Jul 19, 2022 |
| Deutsche Bank | Analyst unavailable | $213 | $203.55 | -18.1% | Jul 13, 2022 |
| Credit Suisse | Analyst unavailable | $233 | $204.36 | -10.4% | Jul 6, 2022 |
| UBS | Analyst unavailable | $246 | $204.36 | -5.4% | Jul 6, 2022 |
| Raymond James | Analyst unavailable | $235 | $204.36 | -9.6% | Jul 6, 2022 |
| Atlantic Equities | Simon Clinch | $235 | $200.43 | -9.6% | Jun 10, 2022 |
| UBS | Analyst unavailable | $258 | $204.68 | -0.8% | Jun 3, 2022 |
| Deutsche Bank | Analyst unavailable | $210 | $190.15 | -19.2% | May 19, 2022 |
| Argus Research | Stephen Biggar | $230 | $200.1 | -11.5% | May 16, 2022 |
| Citigroup | Analyst unavailable | $280 | $223 | +7.7% | Apr 28, 2022 |
| Credit Suisse | Analyst unavailable | $259 | $223.03 | -0.4% | Apr 28, 2022 |
| Raymond James | Analyst unavailable | $254 | $225.93 | -2.3% | Apr 28, 2022 |
| UBS | Alex Kromm | $269 | $237.46 | +3.5% | Apr 5, 2022 |
| Jefferies | Daniel Fannon | $258 | $221.8 | -0.8% | Jan 10, 2022 |
| Berenberg Bank | Eoin Mullany | $190 | $215.65 | -26.9% | Nov 2, 2021 |
| Piper Sandler | Richard Repetto | $230 | $192.18 | -11.5% | Oct 1, 2021 |
| Loop Capital Markets | Kenneth Hill | $151 | $197.42 | -41.9% | Apr 29, 2021 |
| Goldman Sachs | Alexander Blostein | $208 | $194.79 | -20.0% | Apr 28, 2021 |
Track every rating change on CME the moment it posts. Free to start.
Start free